Neuronetics, INC 8-K filings

Neuronetics, Inc. announced its second quarter 2026 financial and operating results, highlighting a 9.1% increase in total revenue and a significant reduction in net loss.

Neuronetics appoints Nir Naor as CFO, promotes Cory Anderson, and announces Andrew Macan's departure.

Neuronetics, Inc. successfully concluded its 2026 Annual Meeting, confirming director elections and the approval of a new equity incentive plan.

Neuronetics, Inc. has amended its consulting agreement with Francis X. Brown III to clarify his ongoing role as Interim Principal Financial and Accounting Officer.

Neuronetics announced its first quarter 2026 financial results, reporting an 8% increase in total revenue to $34.5 million, driven by strong U.S. clinic revenue growth.

Neuronetics, Inc. announced the departure of its CFO, Steven E. Pfanstiel, effective May 1, 2026, and reaffirmed its fiscal year 2026 financial guidance.

Neuronetics announced robust fourth-quarter and full-year 2025 financial results, driven by the Greenbrook acquisition, alongside the appointment of Daniel L. Reuvers as its new President and CEO.

Neuronetics and Madryn Asset Management LP have amended their Registration Rights Agreement, streamlining future share resales and securing Madryn's voting support for key proposals at the 2026 annual meeting.

Neuronetics, Inc. announced its Board of Directors approved annual cash incentive compensation awards for its top executives.

Neuronetics, Inc. announced selected preliminary unaudited financial results for the fourth quarter and full year 2025, showcasing significant revenue growth and positive operating cash flow.

Neuronetics, Inc. has amended its credit agreement with Perceptive Credit Holdings IV, LP, modifying requirements for subsidiary guarantors and controlled accounts.

Neuronetics, Inc. announced its Compensation Committee approved significant cash and restricted stock unit awards for its CFO and General Counsel.

Neuronetics, Inc. announced strong third-quarter revenue growth driven by its Greenbrook acquisition, but revised down its full-year 2025 guidance and revealed CEO Keith J. Sullivan's planned retirement.

Neuronetics, Inc. announced its second quarter 2025 financial results, securing an additional $10 million in debt funding while adjusting its full-year financial outlook and delaying cash flow breakeven expectations.

Neuronetics, Inc. announced the appointment of Steven Pfanstiel as its new Chief Financial Officer, effective July 15, 2025, while reaffirming its financial guidance for the second quarter and full year 2025.

Neuronetics, Inc. announced the results of its Annual Meeting of Stockholders held on May 22, 2025, where all director nominees were elected, KPMG LLP was ratified as auditor, executive compensation was approved, but a proposal to eliminate supermajority voting requirements failed.

Neuronetics' first quarter 2025 revenue surged 84% year-over-year to $32.0 million, primarily due to the acquisition of Greenbrook.

Neuronetics has updated its financial results for Q4 and the full year 2024 due to non-cash revisions related to the Greenbrook TMS Inc. acquisition and shares outstanding.

Neuronetics announces its fourth quarter and full year 2024 financial results, showcasing revenue growth driven by the acquisition of Greenbrook TMS and FDA clearance for adolescent depression treatment.

Neuronetics' Board of Directors approves annual cash incentive compensation awards for key executives.

Neuronetics, Inc. has priced its public offering of 8,000,000 shares of common stock at $2.25 per share, expecting gross proceeds of $18 million.

Neuronetics finalizes its acquisition of Greenbrook TMS Inc., expanding its footprint in the mental health services sector.

Neuronetics reports preliminary 2024 revenue and provides 2025 guidance, highlighting the impact of the Greenbrook TMS acquisition and expected profitability by Q3 2025.

Neuronetics has finalized its acquisition of Greenbrook TMS, creating a larger entity focused on expanding access to mental health treatments.

Neuronetics has revised its cash flow breakeven target to the third quarter of 2025, following the approval of its acquisition of Greenbrook TMS.

Neuronetics, Inc. has successfully regained compliance with Nasdaq's minimum bid price requirement after its stock price closed above $1.00 for ten consecutive business days.

Neuronetics stockholders voted to approve key proposals, including a charter amendment and share issuance, related to the acquisition of Greenbrook TMS Inc.

Neuronetics implements a strategic reorganization, including a 10% workforce reduction, to focus on growth and improve operational efficiency.

Neuronetics announced record third quarter 2024 financial results, highlighted by a 4% revenue increase and the approval of the Greenbrook TMS acquisition.

Neuronetics has amended its registration rights agreement with Madryn Asset Management, extending the period before Madryn can demand registration of their shares from 180 to 365 days post-merger.